Literature DB >> 23412333

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease.

Anthony H V Schapira1, Matthew E Gegg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23412333      PMCID： PMC3587236          DOI： 10.1073/pnas.1300822110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Phenotype, diagnosis, and treatment of Gaucher's disease.

Authors:  Gregory A Grabowski
Journal:  Lancet       Date:  2008-10-04       Impact factor: 79.321

2.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.

Authors:  Idit Ron; Mia Horowitz
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

4.  Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.

Authors:  Chunzhang Yang; Shervin Rahimpour; Jie Lu; Karel Pacak; Barbara Ikejiri; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

5.  Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism.

Authors:  Amy B Manning-Boğ; Birgitt Schüle; J William Langston
Journal:  Neurotoxicology       Date:  2009-07-02       Impact factor: 4.294

6.  Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity.

Authors:  Thai Leong Yap; Arash Velayati; Ellen Sidransky; Jennifer C Lee
Journal:  Mol Genet Metab       Date:  2012-11-28       Impact factor: 4.797

Review 7.  Molecular and clinical prodrome of Parkinson disease: implications for treatment.

Authors:  Anthony H V Schapira; Eduardo Tolosa
Journal:  Nat Rev Neurol       Date:  2010-05-18       Impact factor: 42.937

8.  Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.

Authors:  Ying Sun; Huimin Ran; Benjamin Liou; Brian Quinn; Matt Zamzow; Wujuan Zhang; Jacek Bielawski; Kazuyuki Kitatani; Kenneth D R Setchell; Yusuf A Hannun; Gregory A Grabowski
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

9.  Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage.

Authors:  Michael W J Cleeter; Kai-Yin Chau; Caroline Gluck; Atul Mehta; Derralynn A Hughes; Michael Duchen; Nicholas William Wood; John Hardy; J Mark Cooper; Anthony Henry Schapira
Journal:  Neurochem Int       Date:  2012-10-23       Impact factor: 3.921

10.  Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.

Authors:  Matthew E Gegg; Derek Burke; Simon J R Heales; J Mark Cooper; John Hardy; Nicholas W Wood; Anthony H V Schapira
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422
View more
  25 in total

Review 1.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

Review 2.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

3.  Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease.

Authors:  Ryan P McGlinchey; Jennifer C Lee
Journal:  Biochem Soc Trans       Date:  2013-12       Impact factor: 5.407

Review 4.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

5.  A GCase chaperone improves motor function in a mouse model of synucleinopathy.

Authors:  Franziska Richter; Sheila M Fleming; Melanie Watson; Vincent Lemesre; Lee Pellegrino; Brian Ranes; Chunni Zhu; Farzad Mortazavi; Caitlin K Mulligan; Pedrom C Sioshansi; Sindalana Hean; Krystal De La Rosa; Richie Khanna; John Flanagan; David J Lockhart; Brandon A Wustman; Sean W Clark; Marie-Françoise Chesselet
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 6.  The association between ß-glucocerebrosidase mutations and parkinsonism.

Authors:  Matthew Swan; Rachel Saunders-Pullman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

Review 7.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

Review 8.  Glucocerebrosidase and Parkinson disease: Recent advances.

Authors:  Anthony H V Schapira
Journal:  Mol Cell Neurosci       Date:  2015-03-20       Impact factor: 4.314

Review 9.  α-Synuclein and mitochondrial dysfunction in Parkinson's disease.

Authors:  Stephen Mullin; Anthony Schapira
Journal:  Mol Neurobiol       Date:  2013-01-30       Impact factor: 5.590

10.  Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease.

Authors:  Laura D Osellame; Ahad A Rahim; Iain P Hargreaves; Matthew E Gegg; Angela Richard-Londt; Sebastian Brandner; Simon N Waddington; Anthony H V Schapira; Michael R Duchen
Journal:  Cell Metab       Date:  2013-05-23       Impact factor: 27.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.